首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1614508篇
  免费   132356篇
  国内免费   2621篇
耳鼻咽喉   21774篇
儿科学   53307篇
妇产科学   46481篇
基础医学   229566篇
口腔科学   47433篇
临床医学   142422篇
内科学   317218篇
皮肤病学   34256篇
神经病学   131165篇
特种医学   65090篇
外国民族医学   474篇
外科学   245545篇
综合类   39881篇
现状与发展   3篇
一般理论   561篇
预防医学   124369篇
眼科学   36655篇
药学   122126篇
  3篇
中国医学   2979篇
肿瘤学   88177篇
  2018年   15211篇
  2016年   13204篇
  2015年   15361篇
  2014年   21125篇
  2013年   31931篇
  2012年   43408篇
  2011年   45619篇
  2010年   26803篇
  2009年   25649篇
  2008年   43607篇
  2007年   45786篇
  2006年   46581篇
  2005年   45218篇
  2004年   44590篇
  2003年   42605篇
  2002年   41704篇
  2001年   75899篇
  2000年   78541篇
  1999年   66587篇
  1998年   17857篇
  1997年   16433篇
  1996年   16419篇
  1995年   16106篇
  1994年   15160篇
  1993年   14285篇
  1992年   55570篇
  1991年   53914篇
  1990年   52711篇
  1989年   50954篇
  1988年   47336篇
  1987年   46679篇
  1986年   44421篇
  1985年   42943篇
  1984年   32117篇
  1983年   27671篇
  1982年   16206篇
  1981年   14507篇
  1980年   13621篇
  1979年   30565篇
  1978年   21168篇
  1977年   17843篇
  1976年   16774篇
  1975年   17641篇
  1974年   21543篇
  1973年   20748篇
  1972年   18918篇
  1971年   17823篇
  1970年   16351篇
  1969年   15329篇
  1968年   14011篇
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
Introduction: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype associated with an increased risk of recurrence and cancer-related death. Unlike hormone receptor-positive or HER2-positive breast cancers, there are limited targeted therapies available to treat TNBC and cytotoxic chemotherapy remains the mainstay of treatment. Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate targeting Trop-2 expressing cells and selectively delivering SN-38, an active metabolite of irinotecan.

Areas covered: This review covers the mechanism of action, safety and efficacy of sacituzumab govitecan in patients with previously treated, metastatic TNBC. Additionally, efficacy data in other epithelial malignancies is included based on a PubMed search for ‘sacituzumab govitecan’ and ‘clinical trial’.

Expert opinion: Sacituzumab govitecan has promising anti-cancer activity in patients with metastatic TNBC previously treated with at least two prior lines of systemic therapy based on a single arm Phase I/II clinical trial. A confirmatory Phase III randomized clinical trial is ongoing. Sacituzumab govitecan has a manageable side effect profile, with the most common adverse events being nausea, neutropenia, and diarrhea. The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer.  相似文献   

2.

Objectives

Expedient extubation after cardiac surgery has been associated with improved outcomes, leading to postoperative extubation frequently during overnight hours. However, recent evidence in a mixed medical-surgical intensive care unit population demonstrated worse outcomes with overnight extubation. This study investigated the impact of overnight extubation in a statewide, multicenter Society of Thoracic Surgeons database.

Methods

Records from 39,812 patients undergoing coronary artery bypass grafting or valve operations (2008-2016) and extubated within 24 hours were stratified according to extubation time between 06:00 and 18:00 (day) or between 18:00 and 6:00 (overnight). Outcomes including reintubation, mortality, and composite morbidity-mortality were evaluated using hierarchical regression models adjusted for Society of Thoracic Surgeons predictive risk scores. To further analyze extubation during the night, a subanalysis stratified patients into 3 groups: 06:00 to 18:00, 18:00 to 24:00, and 24:00 to 06:00.

Results

A total of 20,758 patients were extubated overnight (52.1%) and were slightly older (median age 66 vs 65 years, P < .001) with a longer duration of ventilation (4 vs 7 hours, P < .001). Day and overnight extubation were associated with equivalent operative mortality (1.7% vs 1.7%, P = .880), reintubation (3.7% vs 3.4%, P = .141), and composite morbidity-mortality (8.2% vs 8.0%, P = .314). After risk adjustment, overnight extubation was not associated with any difference in reintubation, mortality, or composite morbidity-mortality. On subanalysis, those extubated between 24:00 and 06:00 exhibited increased composite morbidity-mortality (odds ratio, 1.18; P = .001) but no difference in reintubation or mortality.

Conclusions

Extubation overnight was not associated with increased mortality or reintubation. These results suggest that in the appropriate clinical setting, it is safe to routinely extubate cardiac surgery patients overnight.  相似文献   
3.
4.
5.
6.
7.
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号